Copy Paste Quotes

London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’

Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pill

A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect.

Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS), when the immune system goes into overdrive and attacks the body, leading to organ damage.

Continue reading...

Jun 14, 2026 Pharmaceuticals industry Cancer Immunology

Need the full article?

Use the dedicated news page for the summary, then jump straight to the original source when you want the complete story.